GRI Bio Approves 1-for-28 Reverse Stock Split, Reducing Shares to 540K
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: seekingalpha
- Reverse Stock Split Decision: GRI Bio received shareholder approval on January 15, 2026, for a 1-for-28 reverse stock split, set to take effect on January 23, 2026, which will reduce outstanding shares from approximately 15.02 million to about 540,000, aiming to enhance the stock price to meet Nasdaq listing requirements.
- Cash Payment Arrangement: The reverse stock split will not issue fractional shares but will provide cash payments based on the split-adjusted Nasdaq closing price, ensuring shareholders retain value post-split and potentially boosting shareholder confidence.
- Market Reaction: Following the announcement of the reverse stock split, GRI Bio's stock price fell by 4.21%, indicating a cautious market response to the decision, which may impact the company's short-term market performance and investor sentiment.
- Funding Plan: GRI Bio also announced an $8 million public offering, expected to provide additional funding to support future operational needs and strategic investments, although the reverse stock split may affect the terms of financing.
Analyst Views on GRI
Wall Street analysts forecast GRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRI is 23.00 USD with a low forecast of 10.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.320
Low
10.00
Averages
23.00
High
36.00
Current: 5.320
Low
10.00
Averages
23.00
High
36.00
About GRI
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
